• Explore /
  • Poster
  • / KEYNOTE-905/EV-303: A phase 3 study to evaluate the efficacy and safety of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).

KEYNOTE-905/EV-303: A phase 3 study to evaluate the efficacy and safety of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).

Abstract Poster

Authors

Andrea Necchi

Andrea Necchi

Vita-Salute San Raffaele University; IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy

Andrea Necchi , Jens Bedke , Matt D. Galsky , Neal D. Shore , Evanguelos Xylinas , Calvin Jia , Leonid Dubrovsky , Blanca Homet Moreno , J. Alfred Witjes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Biologic Correlates

Clinical Trial Registration Number

NCT03924895

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS4601)

DOI

10.1200/JCO.2023.41.16_suppl.TPS4601

Abstract #

TPS4601

Poster Bd #

93a

Abstract Disclosures

Similar Posters

First Author: Andrea Necchi

First Author: Christopher J. Hoimes

First Author: Thomas Powles

First Author: Deirdre Jill Cohen